Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies.
52W Range
2ndpctl
Volume
2.49×avg
Market Cap
3.92MUSD
P/E Ratio
-0.8TTM
Div Yield
-ann
Loading chart data...
Current StateState loading
Alaunos Therapeutics, Inc.
TCRTNASDAQ Global Select·USD·Closed
Alaunos Therapeutics, Inc.
TCRTNASDAQ·USD·Closed
$1.60
−3.31%
$1.60
−$0.05 (3.31%)
52W Range
2ndpctl
Volume
2.49×avg
Mkt Cap
3.92MUSD
P/E
-0.8TTM
Div Yield
–ann
TCRT: Alaunos Therapeutics, Inc. Stock Analysis | finqOS
